Bolt Biotherapeutics
BOLT

From March 31, 2025 to June 30, 2025 Issuance of common stock under employee stock purchase plan

a one-for-twenty reverse stock split of its outstanding common stock

From December 31, 2023 to December 31, 2024 Issuance of common stock upon vesting of restricted stock units Issuance of common stock under employee stock purchase plan

From June 30, 2024 to September 30, 2024 Vesting of restricted stock units

From March 31, 2024 to June 30, 2024 Issuance of common stock under employee stock purchase plan Vesting of restricted stock units

From December 31, 2023 to March 31, 2024 Vesting of restricted stock units

From December 31, 2022 to December 31, 2023 Issuance of common stock upon exercise of stock options Issuance of common stock under employee stock purchase plan Issuance of common stock upon vesting of restricted stock units

From June 30, 2023 to September 30, 2023 Vesting of restricted stock units

From March 31, 2023 to June 30, 2023 Issuance of common stock upon exercise of stock options Vesting of restricted stock units Issuance of common stock under employee stock purchase plan

From December 31, 2022 to March 31, 2023 Vesting of restricted stock units

From December 31, 2021 to December 31, 2022 Issuance of common stock upon vesting of restricted stock units Issuance of common stock under employee stock purchase plan Issuance of common stock upon exercise of stock options

From June 30, 2022 to September 30, 2022 Vesting of restricted stock units

From March 31, 2022 to June 30, 2022 Vesting of restricted stock units Issuance of common stock under employee stock purchase plan Issuance of common stock upon exercise of stock options

From December 31, 2021 to March 31, 2022 Vesting of restricted stock units Issuance of common stock upon exercise of stock options Vesting of early exercised options

From December 31, 2020 to December 31, 2021 Issuance of Series C-2 convertible preferred stock, net of issuance cost of $42 Reclassification of convertible preferred stock purchase right liability to equity upon issuance of convertible C-2 preferred stock Conversion of convertible preferred stock to common stock Issuance of common stock upon initial public offering, net of issuance costs of $22,541 Issuance of common stock upon exercise of warrants Issuance of common stock related to stock purchase agreement Issuance of common stock under employee stock purchase plan Issuance of common stock upon exercise of stock options

From June 30, 2021 to September 30, 2021 Issuance of common stock upon exercise of stock options

From March 31, 2021 to June 30, 2021 Issuance of common stock related to stock purchase agreement Issuance of common stock under employee stock purchase plan Issuance of common stock upon exercise of stock options

From December 31, 2020 To March 31, 2021 Issuance of Series C-2 convertible preferred stock, net of issuance cost of $42 Reclassification of convertible preferred stock purchase right liability to equity upon issuance of convertible C-2 preferred stock Conversion of convertible preferred stock to common stock Issuance of common stock upon initial public offering, net of issuance costs of $22,541 Issuance of common stock upon exercise of common stock warrants Issuance of common stock upon exercise of stock options

1.Common stock offered by the company 11,500,000 shares 2.The number of shares of common stock that will be outstanding after this offering is based on 23,021,750 shares of common stock (including shares of preferred stock on an as-converted basis, which includes the conversion of the 5,611,059 shares of Series C-2 preferred stock the company issued and sold in January 2021) outstanding as of September 30, 2020